IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.60) per share. This is a 98.1 percent increase over losses of $(31.53) per share from the same period last year.
Omeros Highlights Presentation Of Data At Annual Meeting Of the American Society Of Nephrology Yesterday
First Report of Narsoplimab's Effects on Complement Activation Markers in Renal Disease Presented at the Annual Meeting of the American Society of Nephrology --
Omeros Corporation (NASDAQ:OMER) today announced that